December 2, 2024 4:35 PM
4 oral GLP-1R obesity drugs in race for approval, Novo Nordisk leads: report
Four oral glucagon-like peptide-1 receptor (GLP-1R) drugs, currently under Phase III trials, are in the race for approval, according to a report. This follows the immense popularity of injectable GLP-1R drugs, such as Novo Nordisk’s Wegovy and Sax...